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Abstract
Introduction—Mitochondrial genetics are an important but largely neglected area of research in 
Alzheimer’s disease. A major impediment is the lack of data sets.
Methods—We used an innovative, rigorous approach, combining several existing tools with our 
own, to accurately assemble and call variants in 809 whole mitochondrial genomes.
Results—To help address this impediment, we prepared a data set that consists of 809 complete 
and annotated mitochondrial genomes with samples from the Alzheimer’s Disease Neuroimaging 
Initiative. These whole mitochondrial genomes include rich phenotyping, such as clinical, fluid 
biomarker, and imaging data, all of which is available through the Alzheimer’s Disease 
Neuroimaging Initiative website. Genomes are cleaned, annotated, and prepared for analysis.
Discussion—These data provide an important resource for investigating the impact of 
mitochondrial genetic variation on risk for Alzheimer’s disease and other phenotypes that have 
been measured in the Alzheimer’s Disease Neuroimaging Initiative samples.
Keywords
Alzheimer’s disease; ADNI; Mitochondrial genetics; Whole mitochondrial genomes; Next-
generation sequencing
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
*Corresponding author. Tel.: 11-801-422-2993; Fax: 11-801-422-0004. kauwe@byu.edu.
1Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database 
(adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or 
provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: 
http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf.
Supplementary data
Supplementary data related to this article can be found at https://doi.org/10.1016/j.jalz.2017.11.013.
HHS Public Access
Author manuscript
Alzheimers Dement. Author manuscript; available in PMC 2018 May 21.
Published in final edited form as:
Alzheimers Dement. 2018 April ; 14(4): 514–519. doi:10.1016/j.jalz.2017.11.013.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
1. Introduction
Alzheimer’s disease (AD), the most common form of dementia, affects >20 million people 
worldwide and is the only one of the top 10 causes of death that has no effective treatments 
[1–3]. Full-time care is required as AD progresses, further impacting patients and their loved 
ones and stressing the health-care system. With incidence expected to increase to 1 in 85 
people by 2050 [2], it is essential to achieve early diagnosis, effective treatments, and a 
better understanding of the underlying etiology.
Understanding the underlying mechanisms of risk for AD is a key for both diagnosis and 
treatment. Swerdlow et al. [4] proposed the Mitochondrial Cascade Hypothesis of AD. 
Briefly, an individual’s genetics determine the baseline mitochondrial function and how 
mitochondria change as a person ages and declining mitochondrial function causes AD-
specific pathologies.
In addition to the evidence provided by Swerdlow et al. [4], several lines of evidence support 
a role for mitochondria in AD. First, mitochondria fundamentally change in a number of 
ways in AD and contribute to its progression and onset [5]: metabolism decreases [6], 
mitochondrial fusion/fission are disrupted [7], mitochondrial concentration (i.e. the ratio of 
mitochondrial genomes to nuclear genomes) decreases in cerebrospinal fluid [8,9], 
mitochondrial morphology changes [4,10], mitochondrial-encoded enzymes in the electron 
transport chain are altered [5,11], amyloid plaques aggregate in mitochondria [12,13], and 
many of these changes take place near plaques [14].
Second, individuals with a maternal family history of AD have as high as 9 times the risk of 
AD compared with individuals with a paternal family history of AD [15,16], or no family 
history. Furthermore, individuals with a maternal family history of AD also score lower on 
cognitive tests [17], have a lower age of onset of AD [15,18], and have more pronounced 
brain abnormalities consistent with AD (e.g. cerebral metabolic changes [19], higher 
amyloid β burden [20], reduction in gray matter volume [21,22], and increased global 
Pittsburgh Compound-B uptake Pittsburgh Compound-B-positron emission tomography 
[23]). Moreover, we found that some of these brain abnormalities are associated with 
mitochondrial haplotypes [24].
This mitochondrial impact on AD risk could be influenced by several factors, including 
differential responses to the oxidative stress, variation in nuclear-encoded mitochondrial 
genes, and variation in the mitochondrial genome. In this article, we focus on an important 
resource for investigating mitochondrial genomic variation and others [25]. Several groups 
have reported a relationship between mitochondrial genetics and risk for AD (summarized in 
Ridge et al. [3], Table 2). Twelve different haplotypes have been implicated in mitochondrial 
genetic studies, but the majority of these were reported only once and not replicated [26–33], 
and six different studies reported no association between mitochondrial genetic variants and 
AD [34–39]. Among reported associations, there is no consensus, and sometimes, results 
appear to be contradictory. For example, Haplogroup U has been reported as both a risk and 
protective haplogroup [28,31,32]. However, potentially explaining the confounding nature of 
discoveries to date, the majority of studies used incomplete sequence data and/or had very 
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small sample sizes [26–39], thus most were underpowered and lacked the resolution to 
identify correlations for all but the most common haplogroups. Only a single study used 
whole mitochondrial data [30], whereas most genotyped only a handful of single nucleotide 
polymorphisms (SNPs). Furthermore, only one study used a large data set, but in this 
particular data set, the authors only genotyped 138 SNPs [39]. In summary, there is strong 
evidence to suggest a relationship between the mitochondrial genome and AD, yet the 
relationship remains undefined.
The Alzheimer’s Disease Neuroimaging Initiative (ADNI) recently sequenced the whole 
genomes, including mitochondrial genomes, of 809 individuals. Each of the genomes was 
analyzed using tools and pipelines developed for diploid genomes. However, these analysis 
pipelines, particularly variant identification that relies on a likelihood model expecting 
diploid sequences, are inaccurate for use on the mitochondrial genome, which is haploid. 
Here, we report not only an AD data set of 809 annotated whole mitochondrial genomes 
with extensive phenotypes (Table 1) but also an appropriate pipeline to analyze 
mitochondrial genomes. We hope to facilitate research in this important area by providing a 
data set and analysis pipeline for future researchers to augment this initial data set.
2. Methods
2.1. Alzheimer’s Disease Neuroimaging Initiative
Data used in the preparation of this article were obtained from the ADNI database 
(adni.loni.usc.edu). The ADNI was launched in 2003 as a public–private partnership and is 
an ongoing, longitudinal, highly collaborative study. The primary goal of ADNI has been to 
test whether serial magnetic resonance imaging, positron emission tomography, other 
biological markers, and clinical and neuropsychological assessment can be combined to 
measure the progression of mild cognitive impairment and used for the early diagnosis of 
AD. ADNI has undergone several phases (ADNI1, ADNI GO, and ADNI 2), with each 
phase adding additional samples. In 2012, 818 ADNI samples were selected for whole 
genome sequencing to further the goals of ADNI. DNA sequence data were collected from 
DNA derived from whole blood. All subjects in our analyses had self-reported ancestry of 
non-Hispanic European American. All the data (whole genome sequence, phenotype, and 
newly assembled and annotated whole mitochondrial genomes) are publically available 
through ADNI (http://adni.loni.usc.edu/data-samples/).
2.2. Genome sequencing, assembly, and variant detection
ADNI genomes were sequenced on an Illumina HiSeq. Reads were paired-end, 100 base-
pair reads. Before read mapping, adapters were removed. ADNI mapped the whole genome 
sequences and called variants using default settings in the Burrows-Wheeler Aligner [40] for 
mapping and standard best practices from the Genome Analysis Toolkit [41,42] for variant 
detection (for details see http://adni.loni.usc.edu/data-samples/genetic-data/wgs/). However, 
these steps needed to be redone for two reasons: First, original mappings were to Hg19. 
Historically, determining a reference mitochondrial genome has been a bit confusing. The 
standard mitochondrial genome, NC_012920, was released first in 1981 (the Cambridge 
Reference Sequence, or CRS) [43] and corrected in 1999 (the new Cambridge Reference 
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Sequence, or rCRS) [44]. NC_012920 is a European haplogroup and thus is a leaf on the 
mitochondrial haplotype phylogenetic tree. A number of other mitochondrial genomes have 
been suggested as the “correct” mitochondrial genome reference, including a reconstructed 
hypothetical mitochondrial genome corresponding to Mitochondrial Eve [45]. Nevertheless, 
NC_012920 remains the standard version of the mitochondrial genome used in 
mitochondrial genetics studies. Hg19, which was used for read mapping by ADNI, has a 
version of the mitochondrial genome, represented as chrM, but sometimes corresponds to 
NC_001807 and sometimes NC_012920. Therefore, to be consistent with mitochondrial 
genetic standards, reads needed to be remapped. Second, the standard Genome Analysis 
Toolkit pipeline includes many steps. One of these steps is the HaplotypeCaller. The 
HaplotypeCaller builds a likelihood model based on possible reconstructed haplotypes in a 
genomic region, but it assumes sequences are diploid. Consequently, mitochondrial genomic 
variants identified using the HaplotypeCaller are likely to include many inaccuracies.
Since chrMand NC_012920 only differ by a few bases, we were able to extract only those 
reads that mapped to chrM (with SAMtools [46]), rather than all reads corresponding to the 
whole nuclear and mitochondrial genomes. Extracted reads were remapped to NC_012920 
using Burrows-Wheeler Aligner. Next, we performed local realignments around indels and 
base recalibration, which are not affected by ploidy, with Genome Analysis Toolkit to refine 
the new mappings. Finally, we used FreeBayes (-p 1 –F 0.6, and removed variants with 
quality less than 20) [47] to joint-call variants and converted the resulting variant call format 
(VCF) file to fasta with vcf2fasta (vcflib, https://github.com/vcflib/vcflib). An overview of 
the whole process is outlined in Supplementary Figure 1.
2.3. Genome annotation
We annotated mitochondrial variants and haplotypes for each sample. We downloaded 9228 
mitochondrial DNA coding and RNA sequence variants and 2792 control region variants 
from MITOMAP [48]. For each variant present in the data sets downloaded from 
MITOMAP, we added complete information (i.e. frequency, source, locus names, etc.) to the 
“Info” column in the VCF file and added the corresponding annotation information to the 
header lines. For each variant that was reported by multiple studies in MITOMAP, we 
included all studies in the annotation.
Next, we annotated mitochondrial haplotypes with Phy-Mer [49]. Phy-Mer reports the five 
most likely mitochondrial haplotypes and a score, where 1 is a perfect score. For each of the 
samples, we selected the top hit. All samples had scores >0.99 except for one that had a 
score of 0.988.
2.4. Variant validation
SNP data from the Illumina 2.5 M Array were collected from the same DNA extraction that 
was used for whole genome sequence (WGS) data collected. We compared 256 
mitochondrial variants genotyped on that array to the variant calls from our WGS analysis 
pipeline. Validation was evaluated by simply looking at the concordance of calls on the 
individual level for the two sets of genotype data.
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3. Results
Mitochondrial genomes were sequenced to an average depth of 2986 reads and ranged from 
an average depth of 1515 reads to 7831 reads. We identified 1649 total mitochondrial 
genetic variants from these genomes, of which 1336 have been previously reported. Samples 
had an average of about 27 variants, with a range of 1 to 96 variants. We validated our 
variant calls using 256 mitochondrial genetic genotypes from an SNP array performed on 
the same samples. Overall, 98.18% of WGS variant calls matched SNP genotypes acquired 
from the array.
We identified 506 different mitochondrial haplotypes in the data set, all of which have been 
previously observed. The majority, 350, only appear in a single sample in the data set. The 
most common haplotype, K1A1B1A, is shared by 15 individuals. When considering only 
the major mitochondrial haplogroup (e.g. H, V, U, etc.), the majority of individuals had 
haplotypes in the H and U groups, 338 and 105, respectively. We report number of 
individuals in each major mitochondrial haplogroup in Table 2 and counts of all haplotypes 
in Supplementary Table 1. These frequencies are similar to those observed in other cohorts 
of non-Hispanic European American ancestry [50]. Several individuals have haplotypes 
reported to be associated with risk for AD: five have haplotype H5 (a risk haplogroup [29]).
4. Discussion
We have presented the application of a novel approach to accurately assemble and genotype 
a data set of whole mitochondrial genomes from the ADNI study. Several accurate 
algorithms exist for calling genotypes in diploid NGS data, but use models that are 
inappropriate for haploid samples. We used existing software, but tested and refined 
parameter settings to achieve high levels of genotype accuracy in our mitochondrial genome 
samples. We validated the identified genotypes by repurposing existing publically available 
data. Our genotypes are >98% concordant with genotypes from Illumina SNP chips in the 
same samples. This high level of accuracy is approaching the expected error rate of SNP 
chips and makes it difficult to definitively determine whether our genotypes, or the SNP chip 
genotypes, are correct.
In addition, we have made these data publically available through the ADNI website. A 
multisample VCF file with mitochondrial genomic variants for each subject is available for 
download from the Download—Genetic Data section of the ADNI repository (http://
adni.loni.usc.edu/data-samples/access-data/). Also included is an .XLSX file with 
mitochondrial haplotype information for each subject. The new data sets are named “ADNI 
WGS Whole mitochondrial genome variants” and “ADNI WGS Whole mitochondrial 
genome—Haplotypes”. This data set is now ready to be applied in AD studies and to help 
elucidate the relationship between mitochondria and AD, which has thus far alluded 
researchers.
Complete mitochondrial genomic data result in high resolution of haplotype definition, 
including large numbers of singleton haplotypes. Methods that group haplotypes in 
evolutionarily meaningful ways are necessary to fully leverage these data. In our previous 
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analyses of complete mitochondrial genomics data, we incorporated TreeScanning to 
concentrate statistical power on evolutionarily meaningful groups of haplotypes 
[24,30,51,52]. This approach has been applied successfully in the study of both 
mitochondrial and nuclear genomic contributions to AD risk and related phenotypes 
[24,30,51,53,54].
The ADNI subjects include AD cases, subjects with mild cognitive impairment, and 
cognitively normal controls. Nearly all of these subjects are also associated with extensive 
clinical, imaging, and fluid biomarker data, including some longitudinal data. As such, they 
provide great value in evaluating the multitude of factors that are associated with AD, 
dementia, dementia progression, and conversion from mild cognitive impairment to 
dementia. While this study is underpowered to identify haplotypes associated with AD risk, 
we anticipate it will serve as the foundation for additional data collection and an expanded 
study in the future. These data will also prove valuable for validation and discovery analyses 
related to the multitude of other phenotypes that are available for these subjects. Association 
analyses using imaging and fluid biomarker data are outside the scope of this study, but we 
anticipate that these data will be leveraged by several groups, including ours, for these kinds 
of analyses.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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RESEARCH IN CONTEXT
1. Systematic review: We reviewed existing literature using PubMed and Google 
to identify data sets with whole mitochondrial genome sequences. Although 
several whole genome data sets have been generated for Alzheimer’s disease, 
none of these specifically addressed the whole mitochondrial genomes, which 
require specialized analytic approaches because they are haploid.
2. Interpretation: Mitochondria have a role in Alzheimer’s disease, but the 
precise role has thus far eluded researchers. A primary impediment is a lack 
sufficient data. Our goals were to (1) develop an approach for analyzing 
whole mitochondrial genomes; and (2) develop a data set of whole 
mitochondrial genomes and make them publicly available to encourage 
research in this important area.
3. Future directions: We anticipate that making this data set and analytical 
approach will facilitate additional studies of the effect the mitochondrial 
genome has on risk for Alzheimer’s disease.
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Table 1
Demographics
Count
Sex
(male/female)
Average
age
APOE status
ε2/ε2,ε2/ε3,ε3/ε3,
ε3/ε4,ε4/ε4,ε2/ε4
Cases 191 126/65 74.42 0/8/74/80/25/4
Controls 279 135/144 74.51 0/35/167/68/7/2
MCI 333 183/149* 71.57* 1/26/162/110/25/9
Total 803 444/358* 73.17* 1/69/403/258/57/15
APOE, apolipoprotein E; MCI, mild cognitive impairment.
Demographic and phenotype information is available for 803 of the 809 mitochondrial genomes in the data set. APOE status refers to APOE 
genotype.
*
Missing data for one sample.
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Table 2
Counts and frequencies of major mitochondrial haplogroups
Major
mitochondrial
haplogroup Count Frequency (%)
# Cases/controls/
MCI/unknown
A 5 0.62 3/1/1/0
B 7 0.87 3/1/3/0
C 3 0.37 0/0/3/0
F 1 0.12 1/0/0/0
H 338 41.78 73/128/133/4
I 27 3.34 4/12/11/0
J 69 8.53 24/18/26/1
K 68 8.41 19/24/25/0
L 33 4.08 5/16/12/0
M 11 1.36 2/4/5/0
N 7 0.87 2/2/3/0
R 5 0.62 1/3/1/0
T 78 9.64 16/25/37/0
U 105 12.98 27/31/46/1
V 28 3.46 4/10/14/0
W 15 1.85 3/2/10/0
X 9 1.11 4/2/3/0
MCI, mild cognitive impairment.
Numbers refer to individuals who have the listed major mitochondrial haplogroup or a subgroup (e.g. individuals with H5 are counted as part of the 
H group in this table).
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